SAN DIEGO, July 1, 2024 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral treatments for patients with cancer and rare diseases, today announced that the Company's President and Chief Executive Officer, Kristin Yarema, Ph.D., will participate in a virtual fireside chat at the Stifel 2024 Virtual Cell Therapy Forum on Tuesday, July 9, 2024 at 7:55am PT | 10:55am ET.
A live webcast of the fireside chat will be available on the Investors & Media Section of Poseida's website, . A replay of the webcast will be available for approximately 90 days following the presentation.
About Poseida Therapeutics, Inc.
Poseida Therapeutics is a clinical-stage biopharmaceutical company advancing differentiated allogeneic cell therapies and genetic medicines with the capacity to cure certain cancers and rare diseases. The Company's pipeline includes investigational allogeneic CAR-T cell therapies for both solid tumors and hematologic cancers as well as investigational in vivo genetic medicines that address patient populations with high unmet medical need. The Company's approach is based on its proprietary genetic editing platforms, including its non-viral piggyBac DNA Delivery System, Cas-CLOVER Site-Specific Gene Editing System, Booster Molecule and nanoparticle gene delivery technologies, as well as in-house GMP cell therapy manufacturing. The Company has formed strategic collaborations with Roche and Astellas to unlock the promise of cell therapies for cancer patients. Learn more at and connect with Poseida on X and LinkedIn.
View original content to download multimedia:
SOURCE Poseida Therapeutics, Inc.
Poseida Investor and Media Relations: Alex Chapman, Senior Vice President, IR & Corporate Communications, IR@poseida.com; Sarah Thailing, Senior Director, IR & Corporate Communications, PR@poseida.com
Poseida Therapeutics,Inc.(納斯達克:PSTX)是一家臨床階段異基因細胞療法和基因醫學公司,致力於推進非病毒治療對於癌症和罕見疾病患者的差異化治療。今天,該公司的總裁兼首席執行官Kristin Yarema博士將於2024年7月9日星期二上午7:55(PT)|上午10:55(ET)參加Stifel 2024虛擬細胞療法論壇上的虛擬爐邊聊天。
爐邊聊天的現場網絡直播將在Poseida網站的投資者和媒體部分提供。演示後約90天可提供網絡直播的重播。
關於 Poseida Therapeutics, Inc.
Poseida Therapeutics是一家處於臨床階段的生物製藥公司,推進具有治癒某些癌症和罕見疾病潛力的差異化異基因細胞療法和基因醫學。該公司的管道包括針對實體瘤和血液腫瘤的臨床前CAR-T細胞療法以及旨在滿足高度醫學需求的臨床前體內基因藥物。該公司的方法基於其專有的基因編輯平台,包括其非病毒piggyBac DNA遞送系統、Cas-CLOVER位點特異性基因編輯系統、Booster分子和納米顆粒基因遞送技術以及內部GMP細胞療法制造。該公司已與羅氏和愛衛方,形成戰略合作,以開發針對癌症患者的細胞治療的前景。欲了解更多信息,請訪問 www.poseida.com,並在X和LinkedIn上關注Poseida。
查看下載多媒體原始內容:
來源 Poseida Therapeutics,Inc。
Poseida投資者和媒體關係:Alex Chapman,IR&Corporate Communications高級副總裁,IR@poseida.com; Sarah Thailing,IR&Corporate Communications高級總監,PR@poseida.com